Skip to main content

Table 1 Demographics of donors and recipients

From: rhErythropoietin-b as a tissue protective agent in kidney transplantation: a pilot randomized controlled trial

Donors (n = 34)

 

rhEPO-b treated n = 19

Placebo n = 20

Demographics

  

age (yrs) median(IQR)

52 (45-58)

53 (46-66)

male n (%)

10 (53%)

13 (65%)

ethnicity white n (%)

19 (100%)

20 (100%)

Cause of death n (%)

  

intra-cranial

haemorrhage

14 (74%)

14 (70%)

other intra-cranial event

1 (5%)

4 (20%)

extra-cranial event

4 (21%)

2 (10%)

Donated kidney

  

ECD kidney n (%)

7 (37%)

10 (50%)

DCD kidney n (%)

12 (63%)

10 (50%)

inotropic support n (%)

12 (63%)

16 (80%)

vasopressin n (%)

9 (47%)

11 (55%)

final creatinine (μmol/L) median(IQR)

61(51-87)

77(66-96)

warm ischaemic time1 mins (range)

17 (12-22)

17 (13-20)

DCD only

Recipients (n = 40)

Demographics

  

age (yrs) median(IQR)

51 (43-63)

54 (41-63)

male n (%)

10 (53%)

14 (70%)

White

13 (68%)

19 (95%)

Asian

5 (27%)

1 (5%)

Afro-Caribbean

1 (5%)

0

BMI median(IQR)

25 (23-27)

25 (23-29)

Cause of ESRD n (%)

  

glomerular disease

8 (42%)

6 (30%)

hypertension

1 (5%)

3 (15%)

reflux nephropathy

4 (21%)

3 (15%)

other

6 (32%)

8 (40%)

Mode of dialysis pre-transplant n (%)

  

haemodialysis

9 (47%)

12 (60%)

peritoneal dialysis

8 (42%)

7 (35%)

pre-dialysis

2 (11%)

1 (5%)

months on dialysis median(IQR)

30 (16-51)

42 (22-52)

previous transplant n (%)

3 (16%)

5 (25%)

anuric pre-transplant n (%)

6 (32%)

7 (35%)

diabetes n (%)

1 (5%)

0

hypertension n (%)

17 (90%)

17 (85%)

rhEPO pre-transplant n (%)

17 (90%)

17 (85%)

days before transplant of last rhEPO median (IQR)

5 (4-11.5)

4.5 (1.8-11.0)

PRA%

  

0-5

14

14

6-84

4

5

>84

1

1

HLA mismatches

  

0

5

4

1-2

5

6

3-4

9

10

Cold ischaemic time hrs.mins (range)

16.52

16.45

(12.19-32.36)

(11.12-28.42)

EPO maintenance post-transplant n(%)

9 (46%)

11 (55%)

Blood transfusions post-transplant (n)

6

11

Packed red cell post-transplant (units)

1.2 ± 0.5

1.9 ± 0.6

Acute rejection episodes in 3 mths post-transplant

5

3

  1. 1warm ischaemic time in DCD was defined as the time from asystole to in-situ cold perfusion.
  2. IQR = interquartile range, BMI = body mass index, ESRD = end stage renal disease, PRA = panel reactive antibodies.